Silvia González, Richard J Wall, John Thomas, Stephanie Braillard, Gino Brunori, Isabel Camino Díaz, Juan Cantizani, Sandra Carvalho, Pablo Castañeda Casado, Eric Chatelain, Ignacio Cotillo, Jose M Fiandor, Amanda Fortes Francisco, David Grimsditch, Martine Keenan, John M Kelly, Albane Kessler, Chiara Luise, Jon J Lyon, Lorna MacLean, Maria Marco, J Julio Martin, Maria S Martinez Martinez, Christy Paterson, Kevin D Read, Angel Santos-Villarejo, Fabio Zuccotto, Susan Wyllie, Tim J Miles, Manu De Rycker
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi , affects millions of people in the Americas and across the world, leading to considerable morbidity and mortality. Current treatment options, benznidazole (BNZ) and nifurtimox, offer limited efficacy and often lead to adverse side effects because of long treatment durations. Better treatment options are therefore urgently required. Here, we describe a pyrrolopyrimidine series, identified through phenotypic screening, that offers an opportunity to improve on current treatments...
December 13, 2023: Science Translational Medicine